KDB73301
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
NGM282, CAS: 1616639-03-2
Advanced Microbiome Therapeutics Accelerate MASLD Recovery by Restoring Intestinal Microbiota Equilibrium and the Gut-Liver Axis in a Mouse Model., PMID:40480642
The effect of aldafermin expressing-Escherichia coli Nissle 1917 along with dietary change on visceral adipose tissue in MASLD mouse model., PMID:40211057
Efficacy and safety of aldafermin for the treatment of metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis., PMID:40147589
Clinical Assessment of Common Medications for Nonalcoholic Fatty Liver Disease: A Systematic Review and Bayesian Network Meta-Analysis., PMID:39963857
Efficacy and safety of the FGF19 analog aldafermin for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis., PMID:39649867
Genetic heterogeneity of engineered Escherichia coli Nissle 1917 strains during scale-up simulation., PMID:39111565
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis., PMID:39028914
The role of FGF19 in metabolic regulation: insights from preclinical models to clinical trials., PMID:39017679
Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials., PMID:38688423
FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis., PMID:38228803
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice., PMID:38074508
Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model., PMID:37839774
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis., PMID:37732990
Effects of FGF19 Analogue Aldafermin in Patients With Bile Acid Diarrhea: A Randomized, Placebo-Control Trial., PMID:37084852
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis., PMID:35970684
Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis., PMID:35814516
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease., PMID:35507280
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial., PMID:35325622
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design., PMID:35325621
Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials., PMID:35060815
Role of hemagglutinin esterase in replication of SARS-CoV-2., PMID:34749582
A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH)., PMID:34727818
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases., PMID:33898959
Recent advances in the treatment of primary sclerosing cholangitis., PMID:33283566
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming., PMID:33115209
The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH., PMID:32794259
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis., PMID:32781086
Evolving Role for Pharmacotherapy in NAFLD/NASH., PMID:32583961
Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed., PMID:32118303
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies., PMID:31771820
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis., PMID:30805949
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial., PMID:30414864
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
